Literature DB >> 21575690

Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction.

Bin Yu1, Tai-Hui Fang, Gao-Hong Lü, Hui-Qin Xu, Jin-Fu Lu.   

Abstract

The effect of Cyclovirobuxine D, an active ingredient from Buxus microphylla, was investigated in the potential prevention of cardiac dysfunction in rats with congestive heart failure. Heart failure was induced by left coronary artery occlusion and verified using echocardiography. Cyclovirobuxine D was administered for 30 days (0.5, 1.0 and 2.0mg/kg, ig) and mortality, cardiac function, hemodynamics, microcirculation, histology and ultrastructure assessments were observed. Results from the present study suggest that Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction and supports the potential for Cyclovirobuxine D as a new therapy for heart failure.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21575690     DOI： 10.1016/j.fitote.2011.04.016

Source DB:  PubMed          Journal:  Fitoterapia        ISSN： 0367-326X            Impact factor:   2.882


  12 in total

1.  Cyclovirobuxinum D suppresses lipopolysaccharide-induced inflammatory responses in murine macrophages in vitro by blocking JAK-STAT signaling pathway.

Authors:  Dan Guo; Jing-Rong Li; Ying Wang; Lin-Sheng Lei; Chuan-Lin Yu; Na-Na Chen
Journal:  Acta Pharmacol Sin       Date:  2014-04-21       Impact factor: 6.150

2.  Cyclovirobuxinum D alleviates cardiac hypertrophy in hyperthyroid rats by preventing apoptosis of cardiac cells and inhibiting the p38 mitogen-activated protein kinase signaling pathway.

Authors:  Jun-Biao Wu; Yuan Zhou; Chun-Ling Liang; Xiao-Jun Zhang; Jie-Mei Lai; Shu-Fang Ye; Hui Ouyang; Jin Lin; Jiu-Yao Zhou
Journal:  Chin J Integr Med       Date:  2016-03-17       Impact factor: 1.978

3.  Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment.

Authors:  Qian Guo; Jiabin Guo; Rong Yang; Hui Peng; Jun Zhao; Li Li; Shuangqing Peng
Journal:  Oxid Med Cell Longev       Date:  2015-05-14       Impact factor: 6.543

4.  Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D.

Authors:  Zhongcheng Ke; Xuefeng Hou; Xiao-Bin Jia
Journal:  Drug Des Devel Ther       Date:  2016-06-28       Impact factor: 4.162

Review 5.  Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin.

Authors:  Wei Shi; Hongkuan Deng; Jianyong Zhang; Ying Zhang; Xiufang Zhang; Guozhen Cui
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

6.  Cyclovirobuxine D Induces Apoptosis and Mitochondrial Damage in Glioblastoma Cells Through ROS-Mediated Mitochondrial Translocation of Cofilin.

Authors:  Lin Zhang; Ruoqiu Fu; Dongyu Duan; Ziwei Li; Bin Li; Yue Ming; Li Li; Rui Ni; Jianhong Chen
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

7.  Cyclovirobuxine D Induced-Mitophagy through the p65/BNIP3/LC3 Axis Potentiates Its Apoptosis-Inducing Effects in Lung Cancer Cells.

Authors:  Cheng Zeng; Tingting Zou; Junyan Qu; Xu Chen; Suping Zhang; Zhenghong Lin
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

Review 8.  Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions.

Authors:  Nichanan Osataphan; Arintaya Phrommintikul; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cell Mol Med       Date:  2020-04-26       Impact factor: 5.310

Review 9.  Therapeutic value of steroidal alkaloids in cancer: Current trends and future perspectives.

Authors:  Prasanta Dey; Amit Kundu; Hirak Jyoti Chakraborty; Babli Kar; Wahn Soo Choi; Byung Mu Lee; Tejendra Bhakta; Atanas G Atanasov; Hyung Sik Kim
Journal:  Int J Cancer       Date:  2019-01-21       Impact factor: 7.396

10.  Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses.

Authors:  Zhaohui Jiang; Lingyun Fu; Yini Xu; Xiaoxia Hu; Hong Yang; Yanyan Zhang; Hong Luo; Shiquan Gan; Ling Tao; Guiyou Liang; Xiangchun Shen
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.